Search 

MEDICAL AND MEDICINE INTL COOPAERATION AND INVESTMENT

We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.

SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs).
Sotio is developing the next generation of potent immunotherapies for patients with cancer. The Company is building its pipeline of attractive oncology programs by pursuing promising early stage candidates backed by strong science through strategic licensing, M&A and in-house discovery efforts. Sotio’s scientific research, translational and clinical development expertise provides the infrastructure to translate early stage science into promising clinical stage assets.

Strategikon Pharma is the developer of Clinical Maestro™, which is an end-to-end elegant cloud-based platform to more efficiently budget, source and manage complex clinical programs. We believe that intuitive technology, complete transparency and effective communication between biopharmaceutical companies and providers will revolutionize the productivity of clinical research.

Clinical Maestro™: Modernize the outsourcing

Established in February 1994 with approval from the State Council, Suzhou Industrial Park (SIP) is the first governmental cooperation project between China and Singapore. Covering an administrative area of 278 sqkm, it is home to 1.19 million people, including 807,800 permanent residents. SIP focuses on three main area, Bio-medicine, AI and nanomaterials.
Over 1400 bio-medicine companies are located in SIP including Alphamab Oncology, Innovent and Cstones.
Science & technology development center provide services to entrepreneurial teams who is looking for a place to start up their business.

SynCore Biotechnology Co., Ltd ("SynCore" 4192:TT) is a new drug and medical devices development company that integrates innovative technological platforms with current unmet medical needs. SynCore has a comprehensive pipeline in the therapeutic areas of oncology, ophthalmology, dermatology and infectious diseases, with experienced R&D, regulatory, manufacturing and commercialization teams.

Syneos Health is the only company in the biopharmaceutical services industry purpose-built to create greater success for our customers. At Syneos Health, clinical and commercial live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.

Syneos Health has around 24,000 + employees globally. We are headquartered in US, North Carolina and has more offices in more than 60 countries worldwide. In China, we have offices in Shanghai, Beijing and Dalian.

We call this new way of collaborative working the Biopharmaceutical Acceleration Model or BAM.